WO2001081548A1 - Novel cell systems having specific interaction of peptide binding pairs - Google Patents
Novel cell systems having specific interaction of peptide binding pairs Download PDFInfo
- Publication number
- WO2001081548A1 WO2001081548A1 PCT/US2001/013006 US0113006W WO0181548A1 WO 2001081548 A1 WO2001081548 A1 WO 2001081548A1 US 0113006 W US0113006 W US 0113006W WO 0181548 A1 WO0181548 A1 WO 0181548A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- protein
- transcriptional activation
- yeast cell
- growth factor
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 222
- 230000027455 binding Effects 0.000 title claims abstract description 129
- 230000003993 interaction Effects 0.000 title claims description 73
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 168
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 139
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims abstract description 108
- 108060001084 Luciferase Proteins 0.000 claims abstract description 98
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 84
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 79
- 238000012360 testing method Methods 0.000 claims abstract description 58
- 230000004568 DNA-binding Effects 0.000 claims abstract description 45
- 230000035772 mutation Effects 0.000 claims abstract description 9
- 238000012217 deletion Methods 0.000 claims abstract description 8
- 230000037430 deletion Effects 0.000 claims abstract description 8
- 102000005962 receptors Human genes 0.000 claims description 104
- 108020003175 receptors Proteins 0.000 claims description 104
- 239000003446 ligand Substances 0.000 claims description 95
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 94
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 94
- 210000005253 yeast cell Anatomy 0.000 claims description 76
- 239000005089 Luciferase Substances 0.000 claims description 74
- 230000000694 effects Effects 0.000 claims description 72
- 239000013612 plasmid Substances 0.000 claims description 66
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 43
- 239000002773 nucleotide Substances 0.000 claims description 39
- 125000003729 nucleotide group Chemical group 0.000 claims description 39
- 108010051696 Growth Hormone Proteins 0.000 claims description 38
- 239000000122 growth hormone Substances 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 35
- 102100038803 Somatotropin Human genes 0.000 claims description 29
- 102100039556 Galectin-4 Human genes 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 26
- 108010001515 Galectin 4 Proteins 0.000 claims description 22
- 108010057464 Prolactin Proteins 0.000 claims description 22
- 102100024819 Prolactin Human genes 0.000 claims description 21
- 230000008859 change Effects 0.000 claims description 20
- 229940097325 prolactin Drugs 0.000 claims description 20
- 108010052090 Renilla Luciferases Proteins 0.000 claims description 19
- 239000003102 growth factor Substances 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 10
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 7
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 101710096438 DNA-binding protein Proteins 0.000 claims description 7
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 7
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 7
- 108020004017 nuclear receptors Proteins 0.000 claims description 7
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 claims description 6
- 102000003951 Erythropoietin Human genes 0.000 claims description 6
- 108090000394 Erythropoietin Proteins 0.000 claims description 6
- 108010013990 Guanylate Cyclase-Coupled Receptors Proteins 0.000 claims description 6
- 102000017178 Guanylate Cyclase-Coupled Receptors Human genes 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 102000015696 Interleukins Human genes 0.000 claims description 6
- 108010063738 Interleukins Proteins 0.000 claims description 6
- 102100020880 Kit ligand Human genes 0.000 claims description 6
- 241000235058 Komagataella pastoris Species 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 6
- 102000004140 Oncostatin M Human genes 0.000 claims description 6
- 108090000630 Oncostatin M Proteins 0.000 claims description 6
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 6
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 6
- 108010003044 Placental Lactogen Proteins 0.000 claims description 6
- 239000000381 Placental Lactogen Substances 0.000 claims description 6
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims description 6
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims description 6
- 101150005828 SWI5 gene Proteins 0.000 claims description 6
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims description 6
- 102000013275 Somatomedins Human genes 0.000 claims description 6
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 6
- 108010085012 Steroid Receptors Proteins 0.000 claims description 6
- 102000007451 Steroid Receptors Human genes 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 229940105423 erythropoietin Drugs 0.000 claims description 6
- 229940125396 insulin Drugs 0.000 claims description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 8
- 101800003838 Epidermal growth factor Proteins 0.000 claims 5
- 102400001368 Epidermal growth factor Human genes 0.000 claims 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 5
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims 5
- 108010002386 Interleukin-3 Proteins 0.000 claims 5
- 102100039064 Interleukin-3 Human genes 0.000 claims 5
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 5
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 5
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 5
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 229940116977 epidermal growth factor Drugs 0.000 claims 5
- 229940126864 fibroblast growth factor Drugs 0.000 claims 5
- 229940079322 interferon Drugs 0.000 claims 5
- 229940053128 nerve growth factor Drugs 0.000 claims 5
- 102000006255 nuclear receptors Human genes 0.000 claims 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 5
- 108010030688 Photinus luciferase Proteins 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 13
- 239000013611 chromosomal DNA Substances 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 102
- 108700008625 Reporter Genes Proteins 0.000 description 70
- 150000001875 compounds Chemical class 0.000 description 51
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 42
- 239000013598 vector Substances 0.000 description 37
- 230000004927 fusion Effects 0.000 description 35
- 238000003556 assay Methods 0.000 description 27
- 239000002299 complementary DNA Substances 0.000 description 26
- 102100020948 Growth hormone receptor Human genes 0.000 description 24
- 108010068542 Somatotropin Receptors Proteins 0.000 description 24
- 239000012634 fragment Substances 0.000 description 23
- 108091034117 Oligonucleotide Proteins 0.000 description 20
- 238000001086 yeast two-hybrid system Methods 0.000 description 19
- 108010002519 Prolactin Receptors Proteins 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 239000006152 selective media Substances 0.000 description 18
- 230000004850 protein–protein interaction Effects 0.000 description 17
- 238000010396 two-hybrid screening Methods 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 102100029000 Prolactin receptor Human genes 0.000 description 12
- 238000010561 standard procedure Methods 0.000 description 10
- 241000242743 Renilla reniformis Species 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 238000006471 dimerization reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 101100353517 Caenorhabditis elegans pas-2 gene Proteins 0.000 description 7
- 108090000331 Firefly luciferases Proteins 0.000 description 7
- 101150050575 URA3 gene Proteins 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 6
- 230000010799 Receptor Interactions Effects 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000813 peptide hormone Substances 0.000 description 6
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 101150009006 HIS3 gene Proteins 0.000 description 5
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 4
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 4
- 230000006916 protein interaction Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- 241000254064 Photinus pyralis Species 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 2
- 101150008604 CAN1 gene Proteins 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 102100028501 Galanin peptides Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101000687489 Sus scrofa Prolactin Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002805 secondary assay Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 (that is Substances 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- 101100064556 Caenorhabditis elegans pek-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010061765 Chromosomal mutation Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000799969 Escherichia coli (strain K12) Alpha-2-macroglobulin Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102100039874 Guanine nucleotide-binding protein G(z) subunit alpha Human genes 0.000 description 1
- 101710097371 Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 101001106516 Homo sapiens Regulator of G-protein signaling 20 Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100409239 Mus musculus Prlr gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 101100448397 Rattus norvegicus Ghr gene Proteins 0.000 description 1
- 102100021289 Regulator of G-protein signaling 20 Human genes 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001651 autotrophic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108010066540 copper thionein Proteins 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010045747 interleukin 3 receptor-like molecule Proteins 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000008606 intracellular interaction Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 101150047627 pgk gene Proteins 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- This invention relates to novel cells which express heterologous fused proteins and methods of screening for compounds having peptide-binding activity, wherein the methods employ the novel cells of the invention.
- cytokine receptor The specific binding of a pair of peptides to each other triggers a vast number of functions in a living cell.
- the specific binding of a ligand to a surface receptor serves as the trigger for cellular responses to many external signals.
- cells respond to a wide variety of circulating peptide hormones, often through single transmembrane domain receptors.
- the cytokine receptor superfamily illustrates the diverse aspects of cellular function and physiological responses. Recent examinations of cytokine receptor function have revealed differing ligand-receptor protein stoichiometries including both 2- protein (ligand/receptor) (Cunningham et al . , 1991; Staten et al .
- the 2-hybrid system involves differential interactions between the separable DNA binding and activation domains of the yeast transcriptional activator Gal4.
- Heterologous proteins are expressed as hybrid proteins fused to either half of Gal4 (see Figure 1; Fields and Song, 1989; Chein et al . , 1991 for discussion of the 2-hybrid system) .
- the positive interaction of the heterologous proteins brings the two halves of the Gal4 protein in close proximity, activating expression of a scorable reporter gene.
- yeast-based platforms link the desired effect of a gene or drug of interest to a change in yeast cell phenotype through the use of reporter genes.
- reporter genes have commonly focused on auxotrophy genes for cell growth on selective media, or the LacZ gene for colorometric endpoint using assays that detect B-galactosidase activity.
- luciferase for example, from Renilla reniformis or Photinus pyralis, as a reporter gene in yeast.
- luciferase has been used extensively as a reporter gene in mammalian cells, analogous use in yeast has not been reported.
- luciferase reporter for use in various yeast platforms, such as yeast two-hybrid for protein interaction studies.
- yeast two-hybrid luciferase reporters provide increases in assay sensitivity, speed, ease, signal:noise ratios, and provide high quality quantitative data to yeast-based assays for a myriad of target identification and drug discovery applications.
- Use of the luciferase reporter gene in yeast provides substantial improvements to yeast- based assays as used for gene identification, protein- protein interaction identification and characterization, high throughput screening platforms, automation of these platforms, investigations of G-protein coupled receptors (GPCRs) , regulation of GPCR signaling pathways, and ion channel studies.
- GPCRs G-protein coupled receptors
- Two-hybrid systems are useful for determining whether a first test peptide sequence has binding activity for a second known peptide sequence, wherein the affinity of the test peptide for the known peptide is unknown.
- Such a system has been used to analyze intracellular proteins such as transcription factors and kinase-target protein interactions (Yang et al . , 1992; Durfee et al . , 1993; Li et al . , 1994) .
- novel modified yeast cells of this invention which use luciferase as a reporter gene, and the novel methods incorporating these cells provide a significant advance for the study and discovery of peptide mimics, including ligand mimics and receptor mimics. At this time, no one has developed an efficient and specific screening system to investigate these areas.
- the present invention permits the investigation of peptide binding pairs, such as a ligand and receptor, wherein the peptides bind via extracellular interactions.
- the present invention creates exponential advantages for the discovery of compounds which can interact as ligands for specific receptors or transducers.
- Potential ligands include, but are not limited to, mammalian hormones with the receptors being a cognate extracellular ligand-binding peptide.
- the present invention describes the use of cell systems which express multiple heterologous proteins, including the two heterologous fused proteins to establish the specific and reversible binding of the ligand and receptor. The specific interaction of the above-described binding is readily detected by a measurable change in cellular phenotype, for example, growth on selective medium.
- novel modified host cells for the expression of heterologous fusion proteins.
- the novel modified host cells comprise: a) a gene sequence encoding a heterologous fusion protein; said fusion protein comprising a first peptide of a peptide binding pair, or segment of said first peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein; b) a gene sequence encoding a heterologous fusion protein, said fusion protein comprising a second peptide of the peptide binding pair in (a) , or a segment of said second peptide, fused to either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in (a) ; c) a reporter gene operatively associated with the transcriptional activation protein, or a portion thereof. d) optionally, a deletion or mutation in the chromosomal DNA of the yeast host cell for the transcriptional activation protein if present in
- the novel modified host cells of the present invention can be used to determine the interaction of a test sample with a selected peptide of a peptide binding pair.
- the cell can be used to determine the interaction of a test sample with a selected ligand or receptor.
- a second aspect of the present invention relates to novel modified cells and screening methods which indicate the interaction of a test sample with a selected peptide and receptor by a recognizable change in phenotype.
- the cell exhibits the change in phenotype only in the presence of a test compound having binding affinity for a peptide of the peptide binding pair, for example, binding affinity for a ligand or its receptor.
- a third aspect of the present invention relates to novel cells and screening methods which permit determining to which peptide of a peptide binding pair a test sample binds .
- a fourth aspect of the present invention relates to novel cells which express three or more heterologous components for the study of higher order multi-protein associations between three or more peptides, for example, such as the study of ligand dependent dimerization.
- a fifth aspect of the present invention relates to novel yeast cells comprising a luciferase gene as a reporter gene and screening methods that indicate the interaction of a test sample with a peptide binding pair by a recognizable change in phenotype consequent to expression of the luciferase gene.
- peptide binding pair refers to any pair of peptides having a known binding affinity for which the DNA sequence is known or can be deduced.
- the peptides of the peptide binding pair must exhibit preferential binding for each other over any components of the modified cell.
- peptide as used in the above summary and herein means any peptide, polypeptide or protein, unless stated otherwise.
- the peptides of a peptide binding pair can be a ligand and its corresponding receptor, or a ligand and any peptide having a known binding affinity for the ligand.
- Heterologous as used in the above summary and herein means peptides which (1) are not expressed by the naturally-occurring host cell or (2) are expressed by the modified host cell by an expression method other than the expression method by which the host cell would normally express the peptide.
- receptor encompasses the terms receptor, soluble receptor, transducer and binding protein.
- the receptor employed is a receptor or soluble receptor, with receptor being more preferred.
- Receptor as used herein means plasma membrane proteins that bind specific molecules, such as growth factors, hormones or neurotransmitters, and then transmits a signal to a cell interior, causing the cell to respond in a specific manner. This term includes single transmembrane proteins.
- Solubl ⁇ a receptor means a non-transmembrane form of a receptor which is able to bind ligand. These are receptors released from a cell either by proteolysis or by alternatively spliced mRNA.
- Binding protein means proteins that demonstrate binding affinity for specific ligand. Binding proteins may be produced from separate and distinct genes. For a given ligand, the binding proteins that are produced from specific genes are distinct from the ligand binding domain of the receptor, or its soluble receptor.
- Transducer means a molecule that allows the conversion of one kind of signal into another, and the molecule is readily known as a transducer for one or more the peptides of a peptide binding pair, for example, a transducer for a ligand/receptor group.
- Figure 1 is a schematic diagram of a cell which expresses, from separate plasmids, two heterologous fused proteins (one being the ligand fused to the activation domain of a transcriptional activation protein and the other fused protein being a receptor fused to the DNA binding domain of the transcriptional activation protein) .
- the Figure shows the expression of the two fused proteins and the binding of the ligand and receptor, which brings together the binding domain and activation domain, reconstituting the transcriptional activation protein.
- UAS Upstream Activation Sequences
- Figure 2 contains photographs of plates which show the results of the growth experiments conducted in Example 1 for stains CY722, CY723, CY724, and CY781 on non- selective medium and selective medium, photographs A and B, respectively.
- Figure 3 is a schematic diagram of a dimer model, in which the ligand binds to a dual receptor system.
- the ⁇ schematic diagram depicts a cell which expresses proteins from three separate plasmids. Two heterologous fused proteins (one fused protein being a first receptor fused to the activation domain of a transcriptional activation protein and the other fused protein being a second receptor fused to the DNA binding domain of the transcriptional activation protein) are expressed and free ligand, (that is, ligand which is not fused to either of the two domains of the transcriptional activation protein) , is expressed from a third plasmid.
- the figure shows the expression of the two fused proteins and the binding of the free ligand and two receptor fusions which brings together the binding domain and activation domain, reconstituting the transcriptional activation protein.
- Figure 4 is a photograph of the growth plate obtained for strains CY846 and CY847 from Example 3, showing ligand-dependent stimulation of receptor dimerization.
- Figure 5 is a graph representing the luciferase activity resulting from a protein-protein interaction between Kv4.3 and KChlPl in recombinant yeast cells.
- Figure 6A is a photograph of media plates demonstrating that strain ybn66, which contains both fusion proteins, fails to grow on media containing cyclohexamide, which is indicative of a productive protein-protein interaction and CYH2 reporter gene activity.
- Figure 6B is a graph representing the luciferase activity found in the ybn66L strain (Table 2) , shown in three separate trials, as compared to a negative control (strain ybn ⁇ 8L) and a positive control.
- Figure 7A is a dose response curve demonstrating the ability of compound SBQ-1B3 to modulate luciferase activity resulting from a hKv4.3N-KChIPl and Q205L/GaZ interaction.
- Figure 7B is a dose response curve demonstrating the ability of compound SBQ-3D10 to modulate luciferase activity resulting from a hKv4.3N-KChIPl and Q205L/GaZ interaction.
- Figure 8 is a graph depicting the luciferase activity present in yeast strain ybnllL, which expresses both the ScFv_E2-pAS and hKChIPl-pACT2 to yield a productive protein-protein interaction. Negative control strains ybnl3L and ybnl5L are also presented.
- Figure 9 is a graph depicting the fold activation of the luciferase reporter gene in yeast strain ybnllL, which expresses both the ScFv_E2-pAS and hKChIPl-pACT2 to yield a productive protein-protein interaction.
- Figure 10 is a graph demonstrating the level of Renilla reniformis luciferase and Photinus pyralis (firefly) luciferase activities in mixed yeast cell cutures. Renilla luciferase activity resultied from the protein-protein interaction of Q205L/GaZ and RGS-Z.
- Figure 11 is a graph demonstrating the level of Renilla reniformis luciferase and firefly luciferase activities in mixed yeast cell cutures. Renilla luciferase activity resultied from the protein-protein ' interaction of 4.3N_pGBT9 and KChIPl_pACT2.
- the modified cell of this inventi'on employs a host cell.
- An effective host cell for use in the present invention simply requires that it is defined genetically in order to engineer the appropriate expression of heterologous fused proteins, reporter (s) and any other desired genetic manipulations.
- the host cell can be any eukaryotic cell, vertebrate or non-vertebrate.
- the host cell can be mammalian as well as amphibian, for example, a Xenopus egg cell.
- the host cell is a fungal cell, for example, Aspergilla or Neuropora.
- the host cell is a yeast cell.
- the yeast host cell is Saccharomyces cerevisiae, Schizosaccharomyces pombe or Pichia pastoris.
- the modified host cell employs at least two genes for separately expressing the two heterologous fusion proteins.
- One of these fusion proteins comprises a first peptide of a peptide binding pair, or segment of said first peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein.
- a second fusion protein comprises the second peptide of the peptide binding pair, or a segment thereof. The second peptide is fused to either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in the first heterologous fused protein.
- the activity of the binding between the peptides of the peptide binding pairs is monitored by the use of a reporter gene, which is operatively associated with the transcriptional activation protein employed in the two fusion proteins.
- the transcriptional activation protein can vary widely as long as the DNA binding domains and the activation domains are known or can be deduced by available scientific methods.
- the transcriptional activation protein can be any protein having two components, a DNA binding component and an activation component, wherein the transcriptional activation protein contains an acidic alpha helix for the activation of transcription.
- the transcriptional activation protein is selected from Gal4, Gcn4, Hapl, Adrl, Swi5, Stel2, Mc l, Yapl, Acel, Pprl, Arg81, Lac9, QalF, VPl ⁇ , LexA, non-mammalian nuclear receptors, (for example, ecdysone) , or mammalian nuclear receptors, (for example, estrogen, androgens, glucocorticoids, mineralocorticoids, retinoic acid and progesterone; see also Picard et al . , 1990).
- the transcriptional activation protein is a yeast protein, and more preferably, the transcriptional yeast protein is selected from Gal4, Gcn4 or Adrl.
- DNA binding protein can be used which functions with an activation domain.
- a DNA binding protein can be substituted for the DNA binding domain of a transcriptional activation protein if the recognition sequences operatively associated with the reporter gene are correspondingly engineered.
- Illustrative of non-yeast DNA binding proteins are mammalian steroid receptors and bacterial LexA (see Wilson et al . , 1990) .
- the reporter gene is generally selected in order that the binding of the domains of the transcriptional activation protein can be monitored by well-known and straightforward techniques.
- the reporter gene is selected based on its cost, ease of measuring its activity and low background, (that is, the activity can be determined at relatively low levels of expression of the reporter gene because of a high signal to background ratio and/or a relatively low or no uninduced activity) .
- the reporter can be any reporter for which its activity can be detected by any means available.
- reporter genes selected from the group of: a) lacZ, Luciferase gene, green fluorescent protein gene, CAT; b) genes complementing auxotrophies, such as HIS, URA, LEU, ARG, MET, ADE, LYS, TRP; c) genes conferring antibiotic resistance, such as neo r and KAN; and d) genes conferring sensitivity to a chemical such as CYH2 or CAN1 (canavine resitance) .
- the reporter gene may be convenient for the reporter gene to prevent growth (CYH2) .
- the activity of the reporter gene is indicated by colorimetric or fluorescent methods and/or by measuring growth of the yeast cell.
- the reporter gene is a luciferase gene, for example, a luciferase gene from Renilla reniformis or Photinus pyralis .
- Luciferase genes from other organisms are well known to those of skill in the art.
- a significant advantage conferred by the use of the luciferase reporter gene for two-hybrid analysis is that it enables conversion of non-automated-agar diffusion based assays dependent on longer assay windows (days),- to a liquid assay with much shorter assay windows (hours).
- luciferase reporter in yeast proves enhanced assay sensitivity over present formats, quantitative data, and enables assay automation, especially for higher throughput (384 well) assay formats.
- the utility of using this reporter system will be overall assay speed, ease, and the rapidness of reporter gene activity (thereby avoiding toxic false positives) , and more simple data capture and processing, permitting easier quantification of data.
- the short assay time (4 hours) adds utility in drug screening applications in avoiding compound toxicity effects due to long (48+ hours) incubation times presently needed for standard autotrophic (HIS3, LYS2, URA3) reporters or counter selection (CAN1, URA3, CYH2) reporters, both of which require cell growth for endpoint determinations.
- the use of the luciferase reporter gene in yeast has application to two-hybrid- based systems.
- the peptide employed in the modified cell is a peptide of a peptide binding pair for which the DNA sequence is known as well as the sequence of the second peptide of the binding pair.
- the peptides can also be peptides of a peptide binding complex which contains two or more peptides which bind each other to form the binding complex.
- the peptides of the peptide binding pair can be a specific ligand and a corresponding receptor or any other peptides which bind to each other preferentially, such subunits of an enzyme.
- the modified cell employing the DNA binding and activation domains of a transcriptional protein can be used to monitor the binding of peptides of a peptide binding pair which bind through extracellular interaction.
- peptides which bind through intracellular interaction can also be employed in any of the novel modified cells and methods of this invention.
- the peptide can be from a mammalian cell or non-mammalian cell.
- One of the most important embodiments of the present invention relates to the application of the novel modified cells and corresponding screening methods of this invention for studying numerous mammalian peptide interactions.
- the mammalian peptides include mammalian ligand/receptor interactions, such as hormone/receptor interactions.
- peptide hormones which can be used in the present invention are peptides selected from, but not limited to, one of the following groups: (a) cytokines, interleukins, hematopoietic growth factors, insulin, insulin-like growth factors, growth hormone, prolactin, interferons, and growth ' factors; (b) ligands for G-protein coupled receptors; (c) ligands for nonvertebrate receptors; (d) ligands for guanylyl cyclase receptors; and (e) ligands for tyrosine phosphatase receptors .
- groups selected from, but not limited to, one of the following groups: (a) cytokines, interleukins, hematopoietic growth factors, insulin, insulin-like growth factors, growth hormone, prolactin, interferons, and growth ' factors; (b) ligands for G-protein coupled receptors; (c) ligands for nonvertebrate receptors
- the peptide is a growth factor selected from the group consisting of epidermal GF, nerve GF, leukemia inhibitory factor, fibroblast GF, platelet-derived GF, vascular endothelial GF, tumor necrosis factor, oncostatin M, ciliary neurotrophic factor, erythropoietin, steel factor, placental lactogen and transforming GF.
- the peptide hormone is a ligand for a G-protein coupled receptor, such as growth hormone releasing factor, secretin, vasoactive inhibitory peptide, glucagon, thyrotropin, interleukin-8, luteinizing hormone (LH) or follicle stimulating hormone (FSH) .
- a G-protein coupled receptor such as growth hormone releasing factor, secretin, vasoactive inhibitory peptide, glucagon, thyrotropin, interleukin-8, luteinizing hormone (LH) or follicle stimulating hormone (FSH) .
- the peptide employed is a nonvertebrate peptide, such as those selected from the group consisting of plant system and insect differentiation peptides.
- the peptide is selected from the group consisting of mammalian peptides, and more preferably, mammalian peptide hormones.
- certain receptors may also be a peptide of a peptide binding pair or peptide binding complex.
- a cell adhesion molecule and (b) an immunomodulatory antigen recognition or presentation molecule or other related peptides.
- cell adhesion molecules are ICAM, VCAM, ECAM, fibronectin, integrin, selectin, and fibrinogen.
- an immunomodulatory, antigen recognition or presentation molecule are T cell receptor complex, B cell receptor complex, Fc receptors, major histocompatibility complex I, major histocompatibility complex II, CD4, CD8, CD27, CD30, and MAC complex.
- transducer proteins may also be a peptide of a peptide binding pair or peptide binding complex.
- the transducer proteins employed can be any transducer protein which binds at least one of the peptides of the peptide binding pair or peptide binding complex.
- Transducer proteins include gpl30, kh.97, AIC2A, and AIC2B.
- the heterologous fused proteins are expressed by transformation of the yeast cell with an autonomously-replicating plasmid capable of expressing the fusion protein, although, alternatively, they can be expressed by chromosomal modification.
- the screening methods of this invention are designed in order to detect the ability of a test sample to affect the binding of a peptide binding pair, for example, ligand-receptor interaction.
- the method comprises determining the activity of the reporter gene upon adding a test sample to a modified host cell of the present invention under conditions suitable to detect the activity in the presence of a sample or under a condition for which the modified host cell exhibits such activity only in the presence of a sample having binding interaction with the peptide binding pair.
- the activity of the reporter gene is determined by measuring a change in a selected phenotype which directly correlates to activity of the reporter.
- the novel modified cells of this invention are readily applied in various screening methods for determining the binding ability of a test sample.
- the test sample may be a peptide, which is preferably about two amino acids in length, or a non-peptide chemical compound.
- the non-peptide test sample includes compounds, complexes and salts as well as natural product samples, such as plant extracts and materials obtained from fermentation broths.
- the modified host cells are cultured under suitable conditions for growth to study the interaction of a test sample on the binding interaction of the peptide binding pair.
- the modified host cells are placed in a growth medium, which preferably contains agar, with the test sample applied to the surface of the growth medium.
- the growth medium is preferably a conventional liquid medium of growth reagents and water, such as yeast synthetic medium (YSM available from BIOIOI ⁇ also see Rose et al . , Methods in Yeast Genetics, 1990)).
- One of the embodiments of the present invention is directed to a novel modified host cell and screening method which indicate the interaction of a test compound with a selected peptide binding pair by a recognizable change in phenotype.
- This modified host cell exhibits the change in phenotype only in the presence of test compound having binding affinity for one of the peptides of the peptide binding pair.
- This host cell is referred to herein as a "rescue" system.
- Normally, a cell response is exhibited when the two domains of the transcriptional activation protein interact.
- a rescue system a positive indication of change in the phenotype does not occur when the two domains of the transcriptional activation protein interact.
- a modified host cell is capable of expressing at least two heterologous fusion proteins. Further, the host cell comprises a reporter gene operatively associated with the transcriptional activation protein, wherein said reporter gene prevents the exhibition of a specific phenotype on a selective medium due to the expression of the transcriptional activation protein or a portion thereof.
- a mutation in the chromosomal DNA of the host cell allows for reversal of the detectable phenotype on the selective medium in the absence of expression of the reporter gene.
- the modified cell grow or survive, or exhibit another selected phenotype.
- the phenotype corresponds to the growth of the cell .
- a secondary screen is employed to determine the specific binding affinity of the test sample, that is, to which peptide of the peptide binding pair the test sample binds.
- the secondary screen employs the novel cells of this invention wherein cells are adapted to exhibit a phenotype or phenotypic change only in the presence of a test sample which binds one peptide of the peptide binding pair.
- One of the preferred methods for determining the specific binding characteristics of the test sample involves employing cells which contain an effective (relatively high) copy number of either fusion protein containing one of the peptides.
- An effective copy number is any copy number sufficient to enable determination of the specific binding of the test sample.
- the gene copy number is at least about 5, and preferably ranges from about 5 to about 50, with higher copy numbers being the most preferred.
- the other fusion protein is maintained at a relatively low (1 to about 2 copies per cell) by either integration into a cell chromosome or by utilizing chromosomal centromeric sequences on the expression plasmid.
- the cell will be more sensitive to the presence of the test sample which binds the second peptide of the peptide binding pair since the limiting amount of second peptide determines the level of the activity of the reporter gene, that is, the change in phenotype observed.
- the cell will be more sensitive to the presence of a test sample which binds the first peptide since the limiting amount of the second peptide determines the level of the activity of the reporter gene, that is, the change in phenotype observed.
- a direct comparison of the effects of a test compound on the phenotypes of the two strains demonstrates the specific protein interaction of the compound.
- the genes expressing the peptides, as well as the reporter gene are preferably expressed by transformation of the host cell with an autonomously- replicating plasmid.
- An additional modified host cell of this invention is directed to cells which can be used to study peptides ligands which employ dual receptors or a receptor and a transducer for activation or transmission of a signal from the binding of multiple peptide binding components, that is , three or more peptide binding components.
- Receptor dimerization is a critical first step for signal transduction for certain classes of receptors. Dimer receptor structures can be composed of identical receptor units, (for example, insulin receptor, IGF-I receptor, PDGF receptor, kinase inert domain receptor (KDR) , or colony stimulating factor (CSF) -I receptor).
- non-identical receptor units for example, IL-6R + gpl30, insulin-IGF-I hybrid receptor, LIF + gpl30, CNTF+gpl30, or various interferon receptors.
- the gene sequence (a) is a gene sequence encoding a heterologous fusion protein; said fusion protein comprising one peptide of a multiple peptide binding complex, or segment of said peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein; and the gene sequence (b) is a gene sequence encoding a heterologous fusion protein; said fusion protein comprising a second peptide of said multiple peptide binding complex, or a segment of said receptor, fused to either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in (a) .
- the modified host cell for studying a multiple peptide binding complex also comprises an appropriate reporter gene and chromosomal mutations for specific analysis of the peptide (ligand/receptor) interaction as discussed infra.
- any two of the peptides can be fused to the two components of the transcriptional activation protein.
- a ligand which interacts via receptor dimerization one can express the receptors as fused proteins with the ligand being expressed as a nonfusion protein.
- This host cell system can be also be applied in studying multiprotein enzyme complexes.
- any multipeptide binding complex one can identify novel peptides which interact with the complex by expressing novel proteins from random complementary DNA sequences, for example, a cDNA library, fused to one of the domains of a transcriptional activation protein.
- a cDNA library fused to one of the domains of a transcriptional activation protein.
- one of the known peptides of the peptide binding complex is fused to the other domain of the transcriptional activation protein while other units of the peptide binding complex are expressed as nonfusion peptides.
- the number of peptides expressed by the modified host cell should only be limited by the available detection means and the capacity of the host cell.
- novel screening methods can be utilized to identify compounds interacting with any peptide binding pair, for example, any receptor and/or ligand. Also, this modified cell system with a reporter gene to create a screen can be applied to any protein-protein interaction to discover novel compounds that disrupt that interaction.
- protein kinases implicated in cancers can be inserted into the system to rapidly screen for novel compounds that block the kinase-target interaction and thus may serve as unique cancer therapeutics;
- viral coat proteins such as human immunodeficiency virus glycoproteins, and corresponding cell surface receptor proteins, such as CD4
- CD4 cell surface receptor proteins
- the two subunits for the Plasmodium ribonucleotide reductase enzyme can be expressed in the system to screen for compounds which prevent this specific
- Genes encoding fusion proteins are generated by cloning growth hormone (GH) and growth hormone receptor (GHR) cDNA sequences into plasmids containing the coding region for the domains of Gal4.
- DNA binding domain (Gal4) fusions are constructed in pAS2, which is described in Wade Harper et al .
- Gene activation domain (Gal4) fusions are constructed in pACT-II, which is identical to pACT (described in Durfee et al . , 1993) except with a modification of the polylinker region.
- Bgl II Hemagglutinin epitope - Ndel - Ncol - Smal - BamHI - EcoRI - Xhol - Bgl II, as adapted from the polylinker sequence of pAS2 (Wade Harper et al . , 1993).
- the cDNA encoding the mature peptide for porcine GH is generated using standard polymerase chain reaction (PCR) techniques (see Finney, 1993) .
- Oligonucleotides prepared on an ABI oligosynthesizer are designed according to the published cDNA sequence for pig GH (see Su and El-Gewely, 1988).
- a 30 base 5' oligonucleotide contains a Ncol site (5'-
- CATGCCATGGAGGCCTTCCCAGCCATGCCC 3' (SEQ ID NO: 1) and a 27 base 3' oligonucleotide contains a BamHI site (5'- CGGGATCCGCAACTAGAAGGCACAGCT-3' ) (SEQ ID NO: 2).
- the GH cDNA is generated using a pig pituitary lambda gtll library as template source. A 540 bp fragment is obtained, ligated into pCR II vector (Invitrogen Corp.), recombinants are confirmed by restriction enzyme digest, and the DNA produced as described in Maniatus et al . , 1982.
- the cDNA sequence is confirmed by di-deoxy terminator reaction using reagents and protocols from Perkin-Elmer Cetus Corp. and an ABI 373A automated sequencer.
- the GH cDNA is directionally cloned into pACT-II via Ncol and BamHI sites.
- the cDNA encoding the extracellular domain of the GHR is generated using standard PCR methods.
- a 33 base 5' oligonucleotide containing a Ncol site (5'-
- CATGCCATGGCCTACCGGAAATCTTCTTCACATGCTGCC-3 ' (SEQ ID NO: 4) are used to generate a 742 bp fragment encoding amino acids 1-247 of the rat GHR (Baumbach et al . , 1989).
- This GHR cDNA is cloned into vector pCRII as previously described above, and then subcloned into the Ncol site of vector pAS2.
- DNA of the final recombinant vectors is transformed into yeast strain (s) by the lithium acetate method (Rose et al . , 1990).
- a yeast host (Y190) containing a UAS G ⁇ L -HIS reporter gene is prepared according to the procedure described in Wade Harper et al . , 1993.
- the genotype of strain Y190 is MATa leu2-3,112 ura3-52 trpl-901 his3d200 ade2-101 gal4 gal80 URA3: :GAL-lacZ LYS2 : : GAL-HIS3 cyh r .
- Strain Y190 is transformed with both fusion constructs or with a single fusion construct plus the opposing vector containing no heterologous sequences. All strains are found to exhibit equal growth on nonselective medium ( Figure 2A) .
- strains are then tested for growth on selective medium, that is, a growth medium lacking an amino acid which is synthesized by activation of the reporter gene. Only the strain containing both hybrid proteins (CY722) is able to grow, while the strains containing either the ligand or receptor fusion alone do not grow (CY724 and CY723, respectively; Figure 2B) .
- Two independent samples of each strain are streaked on synthetic medium containing 2% glucose, yeast nitrogen base-, ammonium sulfate, 0.1 mM adenine and 60 mM 3-amino-triazole (plate B) or on the same medium supplemented with histidine (plate A) . Plate A is incubated at 30 C for three days; plate B for five days.
- Example 1A Competing Expressed Free Ligand (GH) in the Presence of GH and GHR Fusion Proteins .
- the system is modified to add a third plasmid mediating expression of "free" ligand to show that the GH peptide competes with the GH-Gal4 fusion protein, reversing the 2- hybrid interaction shown in Example 1.
- the parental strain Y190 (Wade Harper et al . , 1993) is grown on a medium containing 5-fluoro-orotic acid to select for derivatives that spontaneously lose the URA3 gene (see Rose et al . , 1990).
- the resultant strain designated CY770, is utilized for all experiments examining the effects of protein expressed concurrently from the third component, (that is, the third plasmid) .
- the cDNA encoding GH is generated by PCR methods using a 38 base 5' oligonucleotide containing an EcoRI site (5'- CCGAATTCAAAATGGCCTTCCCAGCCATGCCCTTGTCC-3 ' ) (SEQ ID NO: 5) and a 26 base 3' oligonucleotide containing a Hindlll site (5'CCAAGCTTCAACTAGAAGGCACAGCT-3' ) (SEQ ID NO: 6) for subsequent subcloning into the vector pCUP.
- pCUP is an inducible yeast expression vector derived from pRS316 (Hill et al . , 1986).
- this vector is constructed by inserting the 3' end of the yeast PGK gene (from pPGK; Kang et al . , 1990) into the pRS316 cloning region as a BamHI-Sall fragment to serve as a transcriptional terminator.
- the CUP1 promoter region (Butt et al . , 1984) is amplified by PCR as a SacI-EcoRI fragment and inserted into corresponding sites of the plasmid to create pCUP.
- the GH expression plasmid (GH- pCUP) is then co-transformed with the GH and GHR fusion constructs into strain CY770 to generate CY781.
- Example IB Binding of Peptide Hormone Prolactin (PRL) and its Receptor
- Prolactin is structurally related to GH and the prolactin receptor (PRLR) is also a member of the cytokine receptor superfamily. Unlike human GH, sub-primate GH does not readily bind the PRLR (Young and Bazer, 1989) ; nor does PRL readily bind the GHR (Leung et al . , 1987). Mature porcine PRL is generated as a fusion to the GAL4 activation domain. Oligonucleotides are designed to pig PRL (obtained from GenBank; Accessign No.
- a 31 base 5' oligonucleotide includes an EcoRI site (5 1 - CGGAATTCTGCCCATCTGCCCCAGCGGGCCT-3' ) (SEQ ID NO: 7) and corresponds to sequences encoding amino acids 1-7.
- a 30 base 3' oligonucleotide contains an EcoRI site (5'- GAATTCACGTGGGCTTAGCAGTTGCTGTCG-3 ' ) (SEQ ID NO: 8) and corresponds to a region of cDNA 3' to the endogenous termination codon.
- a 600 bp fragment is obtained, ligated into vector pCR II, and confirmed by restriction enzyme digest and sequence analysis.
- the PRL cDNA is cloned into pACT-II via the EcoRI site.
- the extracellular domain of the porcine PRL receptor is generated as a fusion to GAL4 DNA binding domain.
- Oligonucleotides are designed based on sequence of the mouse PRLR (Davis and Linzer, 1989) A 31 base 5' oligonucleotide contains a S al site (5'-
- TCCCCCGGGGATGTCATCTGCACTTGCTTAC-3' (SEQ ID NO: 9) while the 31 base 3' oligonucleotide contains a termination codon followed by a Sail site
- Strain Y190 was transformed with the PRL or PRLR fusion expression plasmids either alone (CY727 or CY728, respectively) or together (CY726) . Cells expressing both the PRL and PRLR fusions are able to grow on selective medium while the strains containing either the ligand or receptor fusion alone can not.
- PRL-pCUP is constructed in a fashion similar to that described for GH- pCUP.
- the PRL cDNA is generated by PCR using a 33 base 5' oligonucleotide with an EcoRI site (5'- GAATTCAAAATGCTGCCCATCTGCCCCAGCGGG-3' ) (SEQ ID NO: 11) and the 3' oligonucleotide in example IB.
- the resulting fragment is introduced into pCUP via the EcoRI site.
- a strain expressing the GH and GHR fusions with no competitor grows on selective medium and this growth is abolished with coexpression of free GH.
- the prolactin experiment produces similar results, which confirms the specificity of the ligand-receptor binding in the yeast cell.
- a strain carrying PRL and PRLR fusions (CY787) can grow on selective medium and this growth is abrogated by expression of free PRL (CY786; Table 1) .
- ⁇ All yeast strains are derived from strain Y190 (Wade Harper et al. 1993). The genotype is MATa gal4 gal80 his3 trpl-901 ade2-101 ura3-52 leu2-3,112 URA3::GAL-lacZLYS2::GAL-HIS3 cyk. Strains with number designations equal to or greater than 770 do not have the URA3::GAL-lacZ gene. A dash indicates that a strain does not contain the denoted plasmid.
- ⁇ AD fusions are pACT derivatives; GH or PRL fused to the Gal4 activation domain.
- BD fusions are pAS2 derivatives; extracellular domains of GH or PRL receptors fused to the D ⁇ A binding domain of Gal4.
- pCUP denotes peptides expressed from the pCUP plasmid. Summary of bioassay results. Each strain is grown on selective medium for 3 to 5 days at 30C then scored for cell growth, indicated by a plus.
- EXAMPLE 2 Screen for compounds disrupting ligand- receptor interaction .
- Gal4 fusion proteins (pOZ153 and pOZ152, respectively) are constructed to reduce expression of these proteins.
- a novel reporter gene is constructed that prevents cell proliferation on selective medium unless expression is abrogated.
- pASl SacI-BamHI restriction fragment containing a yeast constitutive promoter and GAL4 sequences is isolated from pASl (Durfee et al . , 1993) and cloned into pUN30 (Elledge and Davis, 1988) .
- the extracellular domain of GHR is then fused to GAL4 by ligation as an Ncol fragment as described in Example 1 to create pOZl53.
- the entire GH-Gal4 region with promoter and terminator sequences is isolated from the plasmid described in Example 1 as a Pvul-Sall fragment. This DNA segment is cloned into pUNlOO (Elledge and Davis, 1988) generating pOZ152.
- a reporter gene is constructed by isolating the yeast CYH2 coding region and operatively linking it to a GAL promoter in a yeast expression plasmid. Briefly, the GAL1 promoter region is inserted into YEp352 (Hill et al . , 1986) as a 685 bp EcoRI-BamHI fragment.
- CYH2 sequences are amplified by PCR using oligonucleotides primers (5 ' -GGATCCAATCAAGAATGCCTTCCAGAT- 3") (SEQ ID NO: 12) and 5 ' -GCATGCGTCATAGAAATAATACAG-3 ' ) (SEQ ID NO: 13) and pAS2 as the template.
- the PCR product is digested with BamHI plus Sphl and cloned into the corresponding sites in the YEp352-GAL vector.
- These plasmids are transformed into yeast strain CY770 which carries a mutation at the chromosomal cyh2 gene rendering the strain resistant to the protein synthesis inhibitor cycloheximide.
- the presence of all three plasmids is necessary to confer cycloheximide sensitivity (cyh s ) .
- the strain (CY857) containing the ligand and receptor fusion plasmids plus the reporter plasmid forms the basis of a simple primary screen for compounds that disrupt the binding of GH to its receptor.
- Strain CY857 is embedded in standard yeast growth medium containing 10.0 ig/ l cycloheximide. Due to the ligand/receptor interaction driving expression of the CYH2 reporter gene, the strain is cyh s and thus unable to grow. Chemical compounds are placed on this test medium. Compounds which impair GH-GHR binding are identified by the growth of cells surrounding the compound because in the absence of CYH2 expression the cells become resistant to cycloheximide present in the medium.
- Disruption of ligand-receptor binding in this assay can result from reaction of the compound with either the receptor or ligand fusion component.
- the specific target of the novel compound is determined by a simple secondary assay utilizing strains overexpressing one of the fusion proteins.
- Strain CY858 expresses the GHR-GAL4 fusion in large excess due to the construct being maintained within the cells at high copy number (pOZ149) , while the GH-fusion (pOZ152) is maintained at levels similar to the base strain (CY857).
- strain CY859 expresses the GH-GAL4 fusion in large excess due to this construct being maintained within the cells at high copy number (pKY14) , while the GHR fusion (pOZ153) is maintained at levels similar to base strain (CY857) .
- Compounds rescuing growth in the primary screen using CY857 GH and GHR fusions expressed on low copy numbers plasmids are then assayed in the same manner using CY858 (GHR»GH) or CY859 (GH»GHR) as the test strain.
- CY858 GHR»GH
- CY859 GH»GHR
- One unit of the receptor dimer is generated as a fusion protein with either the Gal 4 DNA binding or activation domain.
- the other unit of the receptor dimer is generated as a fusion protein with corresponding Gal DNA binding or activation domain, whichever is not used for the first fusion.
- the gene encoding the ligand is expressed from the third plasmid and is produced as a free (non-fusion) ligand. Interaction of the fusion proteins occurs only in the presence of ligand ( see Figure 3) .
- VEGF vascular endothelial cell growth factor
- KDR kinase insert domain containing receptor
- cDNA encoding the ligand domain of KDR (Terman et al . , 1991) is isolated as an NCO I - BamHI fragment and cloned into both the pACT-II and pAS2 vectors.
- the cDNA encoding the mature protein for VEGF is generated using standard PCR techniques.
- Oligonucleotides are designed from published sequence (see Fischer et al . , 1991).
- a 34 base 5" oligonucleotide containing an EcoRI site (5'- CGGAATTCGAAGTATGGCACCCATGGCAGAAGGA-3 ' ) (SEQ ID NO: 14) and a 28 base 3' oligonucleotide containing an EcoRI site (5'- CGGAATTCGGATCCTCATTCATTCATCA-3' ) (SEQ ID NO: 15) are used to generate a 450 bp fragment encoding the mature protein and cloned into the EcoRI site of pCUP .
- DNA of final recombinant vectors is transformed into yeast by the lithium acetate method to generate appropriate strains.
- the yeast host strain (CY770) is transformed with
- CY846 or transformed with both receptor fusions and pCUP to generate strain CY847. Additionally, both KDR-pACT-II and KDR-pAS2 are transformed together (CY845) or separately (CY843 or CY844) or VEGF-pCUP alone (CY841) as control strains. Strains are tested for growth on selective medium. The strain (CY846) that expresses the
- VEGF ligand plus the two receptor fusion proteins exhibits substantial growth on selective media in comparison to the strain CY847, which does not express the VEGF ligand (see
- Example 4 Screen for compounds that act as ligands in a dimer receptor system
- Dimerization (oligomerization) of receptor units is often an important first step in activation of receptors such as those for the growth factors, cytokines, and those described above.
- the novel cell system described in Example 3 can be applied to the discovery of novel compounds which promote (or block) receptor dimerization. Such novel interacting compounds may serve as effective therapeutic agents for pathologies associated with these receptors.
- Plasmids expressing the dimer receptor unit(s) as fusion proteins are generated as discussed in Example 3.
- strain (CY845) containing the KDR-pACT-II and KDR-pAS2 fusions serves as an example of a simple primary screen for receptors which exhibit a dimer structure.
- CY845 is embedded in synthetic agar medium deficient in histidine (Rose et al . , 1990). Test compounds are applied to the top of this test medium. Chemical compounds which induce interaction of the two receptor fusions (in the absence of ligand) results in the reconstitution of the endogenous transcriptional activator, which is linked to a reporter gene, such as HIS3. The reconstitution is identified by growth of cells surrounding the compound.
- Example 5 Generation of yeast two-hybrid strains for Kv4.3 and KChlPl interaction
- the plasmids hKv4.3N-pGBT9 and KChIPl-pACT2 are described in An et al., (2000), and are used to generate appropriate test and control yeast strains for two-hybrid analysis.
- Yeast strains were transformed using a lithium acetate procedure and plated on appropriate media (Rose et al., 1990) All yeast media and reagents are prepared using standard methods.
- Plasmids hKv4.3N-pGBT9, KChIPl-pACT2 and Kpl26 [Gal- luciferase] were transformed into yeast strain CY770 (described in US 5,989,808; Ozenberger and Young, 1995) to generate interaction strain KY140.
- Plasmids pGBT9, KChIPl-pACT2 and Kpl26 were transformed into yeast strain CY770 to generate control strain KY142.
- Plasmids hKv4.3N-pGBT9, pACT2 and Kpl26 were co-transformed into yeast strain CY770 to generate control strain KY143.
- Plasmids pGBT9, pACT2, and Kpl26 were co-transformed into yeast strain CY770 to generate control strain KY144.
- the luciferase reporter plasmid (s) for use in yeast two-hybrid applications were generated as follows. Plasmid pEKl (described in Price et al . , 1995) was digested with BamHI+Sall restriction enzymes, dephosphorylated, and gel purified. The luciferase coding region was obtained as a Bgl II - Sal I 1.9 kb cDNA fragment from pGL3Basic (Promega) , purified, and ligated to the prepared pEKl vector using standard procedures to generated plasmid Kpl26. The recombinant DNA is transformed into DH5 ⁇ E. coli using standard procedures and plasmid DNA prepared.
- Kpl26 was used extensively for yeast two-hybrid systems and retains the original mammalian Kozak sequence from original DNA source.
- the URA3 marked pRS416 vector (Stratagene) was digested with Smal, dephosphorylated, gel-isolated and purified.
- the Gall/lOp-Luciferase cassette was obtained from Kpl26 by digestion with EcoRI+MluI to generate a 3.5 kb fragment containing promoter, luciferase ORF and ste7 terminus.
- the cDNA fragment was blunt-ended, gel-isolated and purified and ligated into the prepared pRS416 vector to generate the resultant recombinant plasmid Kpl32. Plasmid Kpl32 was transformed into bacterial cells and DNA was prepared and confirmed by restriction analysis.
- a TRPl marked version of the CEN luciferase plasmid Kpl32 was generated.
- a Mlul fragment containing the Gall/10—luciferase—STE7 term cassette from Kpl26 was obtained, blunt ended and ligated into an appropriately prepared pRS414 backbone to generate plasmid Kpl37.
- This recombinant plasmid was transformed into bacterial cells, and DNA was prepared using standard techniques.
- luciferase assays were performed. Briefly, colonies were inoculated in 3 mis SC- , - leucine, -tryptophan- uracil yeast medium and grown overnight at 30°C. Cell density was measured at OD600 and densities were adjusted to an OD 6 oo of 0.2. Cells are seeded in 96-well plates (100 ul) and grown for an additional 2-3 hrs. Luciferase substrate (LucLite, Packard) was added (100 ul) , and the plate was incubated for 50 minutes, in the dark at room temperature, while shaking. Luciferase activity was determined using a 2 second read on a TopCount luminometer (Packard) .
- Analogous yeast strains were generated using 4.3N- pGBT7 and KChlPl-pACT2 with a low copy number version of the Gal-luciferase reporter (Kpl32) .
- Plasmids hKv4.3N- pGBT9, KChIPl-pACT2 and Kpl32 [CEN based Gal-luciferase] were transformed into yeast strain CY770 (described in US Patent No. 5,989,808; Ozenberger and Young, 1995) to generate interaction strain KY183.
- Plasmids pGBT9, KChIPl-pACT2 and Kpl32 were transformed into yeast strain CY770 to generate control strain KY186.
- Plasmids hKv4.3N- pGBT9, pACT2 and Kpl32 were co-transformed into yeast strain CY770 to generate control strain KY185. Plasmids pGBT9, pACT2, and Kpl32 were co-transformed into yeast strain CY770 to generate control strain KY188. Luciferase assays were performed as described previously. Initial testing of the low copy number plasmid demonstrates that the absolute luciferase signal was approximately one third of that generated using a 2-micron version of the luciferase reporter when tested in a similar hKv4.3 and KChlPl two-hybrid interaction. However, the CEN version of the luciferase reporter still provides a 100-fold increase in luciferase activity of test strain in comparison to negative control strain (see Figure 5; left side) .
- luciferase activity showed a 30-fold increase in the strain that contained both fusion proteins, in comparison to a yeast strain that contained only one fusion protein and an empty vector.
- Example 6 Yeast two-hybrid system that employs the luciferase gene as a reporter gene (G-alphaZ and RGSZ interaction)
- G-alphaZ G-alphaZ
- Molecular cloning techniques were carried out using standard methods (Curr Prot. In Mol. Biol). Restriction digests were performed as to manufacturer's specifications. Where appropriate to the cloning scheme, cDNA fragments were end-filled to generate blunt ends using Klenow, and standard techniques. Dephosphorylation of cDNA fragments and/or vectors was conducted using Shrimp Alkaline Phosphotase (SAP) according to manufacturer' s instructions (Boehringer Manheim or Amersham Life Science) .
- SAP Shrimp Alkaline Phosphotase
- the complete ORFs for G-alphaZ and RGS-Z were isolated from a human brain cDNA library (Quickclone cDNA, Clontech) by PCR amplification. PCR primers were designed 5' and 3' of the open reading frame of G-alphaZ (GenBank#J03260) and RGS-Z (Genbank#AF074979) . PCR amplification was performed under standard buffer conditions using the Clontech cDNA Advantage cDNA-kit.
- the primers were G-alphaZ-fwd 5' ACCATGGGATGTCGGCAAAGCTCAGAGGAAA-3' (SEQ ID NO: 17) and G- alphaZ-rev 5' -CAAGGGGTGGGGGACATT-3' (SEQ ID NO: 18) for G- alphaZ and RGS-Z-fwd 5' -CCCGGCCGGCAGGTGGAC-3' (SEQ ID NO: 19) and RGS-Z-rev 5' -CTCATGCAAAATAAAAGTGGTTC-3' (SEQ ID NO: 20) for RGS-Z.
- Cycle parameters were 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute for a total of 30 cycles.
- the pCRII plasmid containing the entire ORF of G- alphaZ was digested with Ncol and EcoRI .
- the insert containing the G-alphaZ ORF was gel purified and ligated directionally in frame in the Ncol and EcoRI sites of the vectors pGBKT7 (Clontech) and pACT2 (Clontech) to generate GaZ-pGBKT7 and GaZ-pACT2, respectively.
- the pCRII plasmid containing the entire wild-type ORF of RGS-Z was digested with Xhol and BamHI , blunt-ended, and after gel- purification, the insert was ligated in frame in the S al site of pGBKT7 and pACT2 to generate RGSZ-pGBKT7 and RGSZ- pACT2, respectively.
- a constitutively active (Q205L; Wang et al . , 1998) form of G-alphaZ was generated.
- the Q205L mutation in G- alphaZ was generated in the GaZ-pGBKT7 and GaZ-pACT2 plasmids using the QuickChange kit (Stratagene) and the primers 5' -GTGGGGGGGCTGAGGTCAGAG-3' (SEQ ID NO: 21) and 5'-CTCTGACCTCAGCCCCCCCAC-3' (SEQ ID NO: 22 ) .
- Recombinant mutant plasmids were transformed into bacterial cells and DNA isolated using standard methods.
- the Q205L G-alphaZ mutants were identified by sequence analysis of the resulting colonies and termed Q205L/GaZ-pGBKT7 and Q205L/GaZ-pACT2.
- Yeast strains were transformed using a lithium acetate procedure and plated on appropriate media (Rose et al., 1990) . All yeast media and reagents were prepared using standard methods. Yeast transformants for appropriate test and control strains were grown for 3-4 days at 30°C on plasmid retention media. The activation and binding domain vectors containing Q205L/GaZ and RGS-Z were transformed into yeast strain CY770 (Ozenberger and Young, 1995) together with a ura-marked plasmid containing either the cycloheximide (CYH2) reporter (pOZl46; US 5,989,808; Young et al., 1998) or the luciferase reporter (Kpl26) . The generated yeast strains and designations are summarized in Table 2.
- the two-hybrid interaction strains co-expressing Q205L/GaZ and RGS-Z fusion proteins in CY770 in combination with the cycloheximide (CYH2) reporter were tested.
- the negative control colonies expressing Q205L/GaZ, or RGS-Z with an empty vector continue to grow on cycloheximide (See Figure 6A) .
- Q205/GaZ-pGBKT7 and RGS-Z- pACT2 were also tested for activation of the luciferase reporter in a two-hyrbid system.
- a luciferase assay was performed as described previously. Briefly, colonies were inoculated in 3 mis plasmid retention (SC - leucine, -tryptophan -uracil) yeast medium and grown overnight at 30°C. Cell density was measured at OD 6 oo and densities were adjusted to an OD 6 oo of 0.2.
- Luciferase substrate was added (100 ul) , and the plate was incubated for 50 minutes, in the dark at room temperature, while shaking. Luciferase activity was determined using a 2 second read on a TopCount luminometer (Packard) . As shown in Figure 6B, there was a five to ten-fold induction of luciferase activity in the interaction strain when compared to the controls strains. Differences in the level of luciferase detected between the individual colonies were attributed to slight variability in the 2 micron plasmid copy number or by individual colony growth rates.
- Example 7 Yeast two-hybrid (YTH) single point screening
- Figure 7A shows that compound SBQ-1B3 demonstrates specific modulation of the luciferase activity in the hKv4.3N / (Iv) KChlPl interaction yeast strain versus the Q205L/GaZ and RGS containing yeast strain.
- compound SBQ-3D10 Figure 7B
- Figure 7B has a specific effect (decrease) on luciferase activity in the hKv4.3N/KChIPl interaction in comparison to the Q205L/GaZ and RGS containing yeast strain.
- Example 8 A yeast two-hybrid system that employs the luciferase gene as a reporter gene (anti-KChlPl single chain antibody [ScFv_E2] and hKChlPl (epitope) interaction)
- Molecular reagents for ScFV were generated using the following methods. mRNA was isolated from hybridoma cell lysate (K55/82) and cDNA was prepared by standard methods. Variable light and heavy chain sequences were PCR amplified and assembled using the Recombinant Phage Antibody System (Amersham/Pharmacia) . Assembled single chain antibody PCR products were then TA- cloned in pCRII vector (In vitrogen) and sequence analyzed.
- the ligated products were transformed in competent STBL2 cells (Life Technologies) and plated on appropriate media and were incubated at 30°C. A number of colonies were selected for recombinant DNA preparation and plasmid sequence was confirmed by DNA sequence analysis.
- recombinant yeast two-hybrid plasmids that express the single chain antibody (ScFv_E2-pAS and ScFv_E2-pACT2) were co-transformed with the recombinant yeast two-hybrid plasmids which express the epitope hKChlPl [hKChlPl-pAS and hKChIPl-pACT2] and Kpl26 (Gal- luc) into the parent yeast strain CY770.
- yeast strain [ybnllL] which expresses both the single chain antibody ScFv_E2-pAS with the hKChIPl-pACT2 resulted in a productive protein-protein interaction and drives expression of the downstream luciferase reporter gene when compared to control strains that express either the ScFv_E2-pAS fusion protein [ybnl3L] or the hKChIPl-pACT2 fusion protein [ybnl5L] with a companion empty vector (see Figure 8) .
- the interaction-positive yeast strain ybnllL which contains both the single chain antibody and epitope fusion proteins, resulted in a 75-fold increase in luciferase activity.
- the interaction of the ScFv_E2-pAS and hKChIPl-pACT2 fusion protein also drives expression of a downstream CYH2 gene, and resulted in sensitivity to cycloheximide and lack of cell growth on selective media in comparison to control strains.
- Example 9 Generation of strains using the pEKl-Ren reporter gene
- Renilla reniformis luciferase As a reporter gene, the Renilla reniformis luciferase coding region plus SV40 polyadenylation signal was obtained by an Nhel and BamHI double-digestion of pRL- null vector (Promega; Genbank accesion # AF025844) .
- the 1197 basepair fragment was blunt-ended and ligated to pEK- 1 vector previously digested by BamHI and blunt-ended to generated plasmid pEKl-Ren.
- Recombinant plasmid was transformed into bacterial cells, purified, and confirmed by sequence analysis.
- Yeast strains analogous to those generated for two- hybrid interactions with the Kpl26 (firefly luciferase) were generated using the Renilla luciferase reporter.
- Yeast strain CY770 was co-transformed with plasmids encoding two-hybrid fusion for G-alphaZ (Q205L) , RGS-Z and the reporter pEKl-Ren to generated test and control strains.
- CY770 was co-transformed with hKv4.3- pGBKT7 and KChIPl-pACT2 and the reporter plasmid pEKl-Ren to generate test and control strains as summarized in
- Renilla luciferase as a reporter gene for yeast two-hybrid interactions
- the interaction between hKv4.3N and KChlPl, as well as the interaction between RGSz and Q205L/GaZ were evaluated.
- Appropriate test and control strains were tested as previously described.
- the yeast strain [ybn70L] which expressed both the Q205L/GaZ-pGBKT7 and RGSz-pACT2 fusion proteins resulted in a productive protein-protein interaction to drive expression of the downstream Renilla luciferase reporter gene.
- control strains that express either the Q205L GalphaZ-pAS fusion protein [ybn71L] or the RGSz-pACT2 fusion protein [ybn72L] with an empty companion vector did not reveal any luciferase activity.
- the strain ybn73L that contains both empty vectors (pAS and pACT2) did not exhibit Renilla luciferase gene expression.
- the interaction yeast strain ybn70L, which contains both fusion proteins results in a 40-fold increase in Renilla luciferase activity. Similar results were observed for hKv4.3N and hKChlPl interaction.
- the yeast strain ybn77L that expresses both fusion proteins [from hKv4.3N-pGBT9 and KChIPl-pACT2] resulted in a productive protein-protein interaction able to drive expression of the Renilla luciferase reporter gene. Luciferase activity was much higher in comparison to control yeast strains, ybn78L and yBN79L, which contain a single fusion protein, h4.3N-pGBT9 or KChIPl-pACT2 respectively, and the companion empty vector.
- the productive interaction between the hKv4.3N and hKChlPl fusion proteins resulted in a 25-fold increase in Renilla luciferase activity in a two-hybrid system.
- Example 10 Multiplexes assays using strains expressing different luciferase reporter genes (Firefly Luc reporters and Renilla Luc reporter)
- yeast strain expressing Q205L/GaZ and RGS-Z as fusion proteins and containing the firefly luciferase reporter gene (ybn66L) and the yeast strain expressing the hKv4.3 and KChlPl fusion proteins and containing the Renilla luciferase reporter gene (ybn77L) were tested.
- Yeast cells for each two-hybrid strain were mixed appropriately, and tested for two-hybrid driven luciferase activity following the general luciferase assay as described previously. Yeast cells were seeded into a 96 well plate, and incubated for approximately 3 hours at
- Firefly luciferase substrate Promega or Packard was added and cells were incubated for approximately 30 minutes, shaken at room temperature in the dark. Firefly luciferase activity was determined using a 2 second read on a TopCount luminometer (Packard) . Substrate for Renilla luciferase was then added to the same well(s) and Renilla luciferase activity was determined using a 10 second read on a TopCount luminometer (Packard) . The fold increases in luciferase activities for each yeast strain and with the individual luciferase reporter gene were similar to that observed when tested individually, as a single strain per assay well.
- the multiplexed format is used to evaluate the effects of modulators (small molecules, expressed peptides, or other molecules) of the protein-protein interaction of interest.
- modulators small molecules, expressed peptides, or other molecules
- cells from independent two-hybrid yeast strains are mixed in the appropriate ratio and aliquoted into a 96 well plate. Compounds are added and cells incubated as described previously. Luciferase activity is determined for each reporter gene as described previously. The luciferase activity of each strain is normalized to a compound negative (vehicle control) well. Effect of compound is noted by a change in luciferase activity. A specific effect of a compound on one protein-protein interaction is noted by a change in luciferase activity on only one of the test strains.
- a compound with potential specific effects on hKv4.3 and KChlPl interaction would affect luciferase activity in yeast strain ybn77L, while no effect on luciferase activity would be observed in ybn66L that contains Q205L/GaZ and RGS-Z.
- a compound that blocks the protein-protein interaction would be observed as a decrease in luciferase activity.
- the growth hormone -binding protein in rat serum is an alternatively spliced form of the rat growth hormone receptor. Genes & Devel . 3:1199-1205.
- Kang Y-S Kane J, Kurjan J, Stadel JM and DJ Tipper. (1990) Effects of expression of mammalian G and hybrid mammalian-yeast G proteins on the yeast pheromone response signal transduction pathway. Mol. Cell. Biol. 10:2582-2590.
- Interleukin-2 receptor chain A functional component of the interleukin-7 receptor. Science 262:1877-1880.
- Cipl is a potent inhibitor of Gl Cyclin-dependent kinases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001257157A AU2001257157A1 (en) | 2000-04-24 | 2001-04-23 | Novel cell systems having specific interaction of peptide binding pairs |
MXPA02010446A MXPA02010446A (en) | 2000-04-24 | 2001-04-23 | Novel cell systems having specific interaction of peptide binding pairs. |
JP2001578619A JP2004527204A (en) | 2000-04-24 | 2001-04-23 | Novel cell lines with specific interaction of peptide binding pairs |
BR0110214-1A BR0110214A (en) | 2000-04-24 | 2001-04-23 | Yeast Cell and Methods for Detecting the Interaction of a First Peptide with a Second Peptide of a Peptide Binding Pair, Determining the Interaction of a Test Sample with a First or Second Peptides of a Peptide Binding Pair, and simultaneous detection of the interaction of two different peptide binding pairs |
EP01930643A EP1283870A4 (en) | 2000-04-24 | 2001-04-23 | Novel cell systems having specific interaction of peptide binding pairs |
CA002407382A CA2407382A1 (en) | 2000-04-24 | 2001-04-23 | Novel cell systems having specific interaction of peptide binding pairs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/556,390 | 2000-04-24 | ||
US09/556,390 US6770446B1 (en) | 1994-06-14 | 2000-04-24 | Cell systems having specific interaction of peptide binding pairs |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001081548A1 true WO2001081548A1 (en) | 2001-11-01 |
Family
ID=24221147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/013006 WO2001081548A1 (en) | 2000-04-24 | 2001-04-23 | Novel cell systems having specific interaction of peptide binding pairs |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1283870A4 (en) |
JP (1) | JP2004527204A (en) |
AU (1) | AU2001257157A1 (en) |
BR (1) | BR0110214A (en) |
CA (1) | CA2407382A1 (en) |
MX (1) | MXPA02010446A (en) |
WO (1) | WO2001081548A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1572102A2 (en) * | 2002-11-01 | 2005-09-14 | Decode Genetics EHF. | Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
CN104024409A (en) * | 2011-10-28 | 2014-09-03 | 默沙东公司 | Engineered lower eukaryotic host strains for recombinant protein expression |
GB2549351A (en) * | 2015-11-13 | 2017-10-18 | Asterion Ltd | Fusion polypeptide |
CN113234748A (en) * | 2021-05-11 | 2021-08-10 | 中国海洋大学 | RXR yeast transcription activation system and labeled sediment toxicology experiment method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4900718B2 (en) * | 2005-06-09 | 2012-03-21 | 独立行政法人産業技術総合研究所 | Reporter assay using secretory luminescent enzyme |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5525490A (en) * | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5641641A (en) * | 1990-09-10 | 1997-06-24 | Promega Corporation | Kit for luciferase assay |
US5834209A (en) * | 1993-08-26 | 1998-11-10 | Washington University | Bcl-x/bcl-2 associated cell death regulator |
US5837478A (en) * | 1993-12-23 | 1998-11-17 | Icos Corporation | Method of identifying modulators of binding between and VCAM-1 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5989808A (en) * | 1994-06-14 | 1999-11-23 | American Cyanamid Company | Identification of compounds affecting specific interaction of peptide binding pairs |
-
2001
- 2001-04-23 BR BR0110214-1A patent/BR0110214A/en not_active IP Right Cessation
- 2001-04-23 AU AU2001257157A patent/AU2001257157A1/en not_active Abandoned
- 2001-04-23 CA CA002407382A patent/CA2407382A1/en not_active Abandoned
- 2001-04-23 MX MXPA02010446A patent/MXPA02010446A/en unknown
- 2001-04-23 WO PCT/US2001/013006 patent/WO2001081548A1/en not_active Application Discontinuation
- 2001-04-23 JP JP2001578619A patent/JP2004527204A/en active Pending
- 2001-04-23 EP EP01930643A patent/EP1283870A4/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5641641A (en) * | 1990-09-10 | 1997-06-24 | Promega Corporation | Kit for luciferase assay |
US5834209A (en) * | 1993-08-26 | 1998-11-10 | Washington University | Bcl-x/bcl-2 associated cell death regulator |
US5837478A (en) * | 1993-12-23 | 1998-11-17 | Icos Corporation | Method of identifying modulators of binding between and VCAM-1 |
US5525490A (en) * | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
Non-Patent Citations (1)
Title |
---|
See also references of EP1283870A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1572102A2 (en) * | 2002-11-01 | 2005-09-14 | Decode Genetics EHF. | Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
EP1572102A4 (en) * | 2002-11-01 | 2006-06-14 | Decode Genetics Ehf | Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
CN104024409A (en) * | 2011-10-28 | 2014-09-03 | 默沙东公司 | Engineered lower eukaryotic host strains for recombinant protein expression |
GB2549351A (en) * | 2015-11-13 | 2017-10-18 | Asterion Ltd | Fusion polypeptide |
CN113234748A (en) * | 2021-05-11 | 2021-08-10 | 中国海洋大学 | RXR yeast transcription activation system and labeled sediment toxicology experiment method thereof |
CN113234748B (en) * | 2021-05-11 | 2022-11-08 | 中国海洋大学 | RXR yeast transcription activation system and labeled sediment toxicology experiment method thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2407382A1 (en) | 2001-11-01 |
AU2001257157A1 (en) | 2001-11-07 |
MXPA02010446A (en) | 2003-04-25 |
BR0110214A (en) | 2003-01-21 |
EP1283870A4 (en) | 2004-05-12 |
JP2004527204A (en) | 2004-09-09 |
EP1283870A1 (en) | 2003-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0765389B1 (en) | Cell systems having specific interaction of peptide binding pairs | |
Young | Yeast two-hybrid: so many interactions,(in) so little time… | |
CA2441444C (en) | Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system | |
DE69831083T2 (en) | REPRIMATED TRANS-ACTIVATOR SYSTEM FOR CHARACTERIZING PROTEIN-PROTEIN INTERACTIONS | |
Le Douarin et al. | A new version of the two-hybrid assay for detection of protein-protein interactions. | |
AU650677B2 (en) | Screening assays | |
WO1997008550A1 (en) | Retinoid x receptors and components of the basal transcription machinery | |
JP2013236637A (en) | Chimeric retinoid x receptor and new ecdysone receptor-based inducible gene expression system and their use | |
AU637446B2 (en) | Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors | |
Vidal | The reverse two-hybrid system | |
US6479289B2 (en) | Mammalian two-hybrid system | |
US6770446B1 (en) | Cell systems having specific interaction of peptide binding pairs | |
EP1283870A1 (en) | Novel cell systems having specific interaction of peptide binding pairs | |
Uppaluri et al. | Genetic dissection of thyroid hormone receptor β: identification of mutations that separate hormone binding and transcriptional activation | |
Yamaguchi et al. | Functional analysis of aryl hydrocarbon receptor nuclear translocator interactions with aryl hydrocarbon receptor in the yeast two-hybrid system | |
US7037656B2 (en) | Methods and compositions for identifying ligands for nuclear receptors | |
Bush et al. | Use of the yeast one-hybrid system to screen for mutations in the ligand-binding domain of the estrogen receptor | |
AU2003260308B2 (en) | Method for identifying substances | |
Young | A yeast two-hybrid, systems based approach for the identification of novel pharmaceutical entities | |
Starr et al. | Intracellular receptors use a common mechanism to interpret | |
Jones | A study into the conserved nature of yeast and mammalian transcription factors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/010446 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 578619 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2407382 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001930643 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001930643 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001930643 Country of ref document: EP |